ClinicalTrials.gg
RecruitingNCT05792150PROOFSUpdated Aug 5, 2026

PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS

An observational study in Female Breast Cancer, sponsored by Women's Cancer Study Group GmbH. Recruiting at 71 sites in Germany. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Women's Cancer Study Group GmbH · Observational

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,470
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 678 studies in Breast Neoplasms with a site in Germany — 114 open to participants now, 196 under way, 81 of them phase 3. Breast Neoplasms · Germany.

Planned enrollment
28th of 92
1,470 · median 580
Started
2022
with 30 others
Observational
93 of 678
23 open now
Primary completion
2035-03
later than 194 of 195 live
Registered
569th of 678
by date

Among the 678 studies in Breast Neoplasms with a site in Germany, this one is the 28th largest by planned enrollment of the 92 observational ones that give a count, is one of 31 that started in 2022, is one of 93 observational ones, reaches primary completion later than 194 of the 195 other live ones, and was the 569th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

114 of the 678 studies in Breast Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 678 studies in Breast Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

There is only limited data for premenopausal patients in general, as well as for differences in the use of OFS in the subgroups of pre- and perimenopausal patients, respectively. The WSG ADAPT trial data on the impact of postmenopausal status and/or use of OFS within 3-4 weeks endocrine induction therapy show relevant impact of OFS/postmenopausal status on Ki-67 response; also, secondary amenorrhea after (neo-)adjuvant chemotherapy was a positive predictor of outcome due to OFS [8, 9].

This registry will give insights in the real-world use of OFS and the effect of secondary amenorrhea in female pre- and perimenopausal patients with or without previous use of chemotherapy and with different endocrine treatments (ET +/- GnRH).

As adherence over time (5-10 years) plays a major role in the endocrine treatment, the registry will follow patients' treatments for up to 10 years and include QoL information.

Results of MammaPrint® (MammaPrint® Index) as indicating factor for chemotherapy use and risk classification, thus, choice of adjuvant treatment (chemotherapy, OFS combined with endocrine therapy, or endocrine therapy alone) will be correlated to outcome under real-world conditions.

Baseline, treatment, and relapse data shall be collected to gain further insight in the treatment paths, treatment adherence, and outcome of such patients.

Read the detailed description

This registry aims

  • to confirm an excellent outcome in pre-/perimenopausal patients treated by endocrine therapy (+ ovarian suppression) in patients with low genomic risk by MammaPrint® without chemotherapy use in a real-world setting.
  • to evaluate management of ovarian function in patients treated by adjuvant chemotherapy according to investigator decision.
  • to evaluate adherence to endocrine therapy (+/- ovarian function suppression).
  • to evaluate the prognostic impact of clinicopathological markers (e.g., estrogen receptor (ER), progesterone receptor (PR), HER2 receptor, Ki-67 at baseline and after preoperative endocrine therapy (if any performed) by local pathology assessment compared to genomic signature result.
  • to assess the course of quality of life (QLQ BR23 and QLQ-C30) until 5 years of treatment with OFS (Baseline, 3 months, 6 months, 12 months, 18 months, 2 years, 3 years, 4 years, 5 years)

In general, WSG aim to assess the quality of surveillance care in younger breast cancer patients. WSG want to gain knowledge about endocrine induction treatment for indication of chemotherapy followed by endocrine treatment or endocrine treatment alone. Also, WSG aim at changes in duration of endocrine treatment (especially in high-risk patients up to 10 years) and introduction of intensified endocrine therapy (OFS) in combination with GnRH-analogues since publication of the SOFT and TEXT trials.

03

Conditions studied

  • Female Breast Cancer

Browse trials for

Keywords

  • HR+
  • HER2-
  • EBC
  • early breast cancer
  • female
  • OFS
  • ET
  • chemotherapy
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

For this registry, it is planned to screen N=3000 pre- and perimenopausal patients with early breast cancer who meet the inclusion criteria, i.e., intermediate to high clinical risk for recurrence, and who will receive or have received a routine genomic testing by MammaPrint® with a low/ultralow genomic risk.

It is anticipated that 75% of these patients will be nodal negative and 25% nodal positive.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients are eligible for participation in the registry only if they meet all the following criteria:

  • Female breast cancer patients
  • Pre- or perimenopausal at registry entry (age \<60 years and state after hysterectomy or amenorrhea for \<12 months; confirmation by blood hormone levels (FSH and estradiol in premenopausal range as per local normal range) recommended)
  • Primary tumor diagnosis not older than three months prior to inclusion (primary diagnosis defined as date of initial tumor )
  • Estrogen- and/or progesterone-receptor-positive/ negative early breast cancer without any clinical signs of
  • Adequate risk for recurrence:
  • intermediate clinical risk for recurrence, defined as (clinical in case of treatment):
  • c/pT1 and
  • c/pN0 and
  • Ki-67 15-24% or
  • G2 or
  • patients, who do not meet these criteria but are at intermediate clinical risk for recurrence at investigator decision (e.g., very young age, low expression of hormone receptors, existing co-morbidities, familial cancer burden, etc.) can be included on individual decision basis or
  • high clinical risk for recurrence, defined as either (clinical in case of neoadjuvant treatment):
  • c/pT2-4 or
  • c/pN1 or
  • Ki-67 ≥25% or
  • G3
  • Low genomic risk of recurrence by MammaPrint® (tested on treatment naïve tumor specimen)
  • Luminal-type by BluePrint®
  • Treatment according to standard-of-care (e.g., AGO Guidelines) planned or started (until completion of local therapy the latest (including started or completed endocrine induction therapy), started, or planned adjuvant or neoadjuvant treatment)
  • Availability of untreated tumor material (core biopsy if preoperative endocrine therapy performed or neoadjuvant treatment intended or surgery specimen)
  • Capability to give written
  • Nodal positive patients will be accepted to the registry up to 25% of the genomic low/ultralow-risk population (n=441).

Exclusion criteria

Exclusion Criteria:

Patients will not be eligible for the registry for any of the following reasons:

  • Any other genomic testing, besides MammaPrint®, has been performed on the tumor material
  • Medical or psychological conditions that would not permit the patient to sign
  • Legal incapacity or limited legal capacity
  • Current participation in any interventional clinical trial which tests anticancer drugs, immunotherapeutics, or antibody treatment for any type of neoplasm
  • Non-compliance of the patient
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,470 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. 5-year distant recurrence-free interval (dRFI, according to STEEP criteria version 2.0)

    dRFIin all patients treated by (intensified) endocrine therapy alone (and with ovarian suppression in cases with enhanced clinical risk according to current AGO-recommendations)

    Time frame: 5 years

Secondary outcomes

  1. 10-year dRFI

    dRFI, according to STEEP criteria 2.0, in all patients treated by (intensified) endocrine therapy alone (with ovarian suppression in cases with higher clinical risk)

    Time frame: 10 years

  2. 5-year dRFI

    dRFI, according to STEEP criteria 2.0,in all patients treated by SOC chemotherapy treatment followed by ET+/-OFS

    Time frame: 5 years

  3. 10-year dRFI

    dRFI, according to STEEP criteria 2.0,in all patients treated by SOC chemotherapy treatment followed by ET+/-OFS

    Time frame: 10 years

  4. 5-year dDFS

    distant disease-free survival (dDFS, according to STEEP 2.0) in all patients and all treatment groups (i.e., patients treated by ET alone, ET + GnRH, chemotherapy followed by ET, chemotherapy followed by ET + GnRH, OFS-treated patients)

    Time frame: 5 years

  5. 10-year dDFS

    distant disease-free survival (dDFS, according to STEEP 2.0) in all patients and all treatment groups (i.e., patients treated by ET alone, ET + GnRH, chemotherapy followed by ET, chemotherapy followed by ET + GnRH, OFS-treated patients)treatment followed by ET+/-OFS

    Time frame: 10 years

  6. 5-year OS

    overall survival (OS) in all patients and all treatment groups

    Time frame: 5 years

  7. 10-year OS

    overall survival (OS) in all patients and all treatment groups

    Time frame: 10 years

  8. 5-year breast cancer-free interval (BCFI, according to STEEP 2.0)

    BCFI in all patients and all treatment groups

    Time frame: 5 years

  9. 10-year breast cancer-free interval (BCFI, according to STEEP 2.0)

    BCFI in all patients and all treatment groups

    Time frame: 10 years

  10. EORTC quality of life questionnaire BR23

    compare the course of Qol between baseline and further defined timepoints; 23 items, symptom scales/items and functional scales/items, all of the scales and single-item measures range in score from 0 to 100. A high score for the functional scales represents a high/healthy level of functioning, whilst a high score for the symptom scales represents a high level of symptomatology or problems.

    Time frame: every 3 months within 1st year

  11. EORTC quality of life questionnaire C30

    compare the course of Qol between baseline and further defined timepoints; 30 items, 10 subscales, the higher the rating, the worse.

    Time frame: every 3 months within 1st year

  12. EORTC quality of life questionnaire BR23

    compare the course of Qol between baseline and further defined timepoints; 23 items, symptom scales/items and functional scales/items, all of the scales and single-item measures range in score from 0 to 100. A high score for the functional scales represents a high/healthy level of functioning, whilst a high score for the symptom scales represents a high level of symptomatology or problems.

    Time frame: every 6 months within 2nd year

  13. EORTC quality of life questionnaire C30

    compare the course of Qol between baseline and further defined timepoints; 30 items, 10 subscales, the higher the rating, the worse.

    Time frame: every 6 months within 2nd year

  14. EORTC quality of life questionnaire BR23

    compare the course of Qol between baseline and further defined timepoints; 23 items, symptom scales/items and functional scales/items, all of the scales and single-item measures range in score from 0 to 100. A high score for the functional scales represents a high/healthy level of functioning, whilst a high score for the symptom scales represents a high level of symptomatology or problems.

    Time frame: yearly until 5 years

  15. EORTC quality of life questionnaire C30

    compare the course of Qol between baseline and further defined timepoints; 30 items, 10 subscales, the higher the rating, the worse.

    Time frame: yearly until 5 years

  16. adherence to OFS and endocrine treatment

    Duration of intake of OFS and endocrine treatment in all patients

    Time frame: 10 years

  17. concordance between BluePrint®/MammaPrint® molecular subtyping results vs. pathological immune-histochemistry results

    concordance between BluePrint®/MammaPrint® molecular subtyping results and pathological immune-histochemistry results with respect to tumour type

    Time frame: 10 years

  18. endocrine response measured by post-endocrine Ki-67

    post-endocrine Ki-67 (≤10% and/or relative change vs. baseline) in patients treated by preoperative ET

    Time frame: 10 years

  19. 5-year iDFS in node-negative patients with ultralow MammaPrint

    node-negative patients with ultralow MammaPrint® treated by shorter duration of ET (2-3 years at investigator decision)

    Time frame: 5 years

  20. 10-year iDFS in node-negative patients with ultralow MammaPrint

    node-negative patients with ultralow MammaPrint® treated by shorter duration of ET (2-3 years at investigator decision)

    Time frame: 10 years

07

Study locations

61 of 71 sites recruiting
  • Klinikum-Mittelbaden GmbH, Studienzentrale/Brustzentrum
    Baden-Baden, Baden-Wurttemberg 76532, Germany
    Recruiting
    • Antje Hahn, Dr. med. · Contact
    • Martina Koch · Contact
  • Helios Klinikum Pforzheim, Brustzentrum
    Pforzheim, Baden-Wurttemberg 75175, Germany
    Recruiting
    • Renu Buss-Steidle, Dr. · Contact
    • Dana Ruppert · Contact
  • Diakonieklinikum Stuttgart, Brustzetrum
    Stuttgart, Baden-Wurttemberg 70176, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsfrauenklinik Ulm - Frauenheilkunde und Geburtshilfe
    Ulm, Baden-Wurttemberg 89075, Germany
    Recruiting
    • Brigitte Rack, Prof. Dr. · Contact
    • Mirela Karic · Contact
  • GRN Klinik Weinheim/ Gynäkologie/Brustzentrum
    Weinheim, Baden-Wurttemberg 69469, Germany
    Recruiting
    • Lelia Bauer, Dr. med. · Contact
    • Snjezana Stein · Contact
  • ViDia Christliche Kliniken Karlsruhe
    Karlsruhe, Baden-Wüttemberg 76135, Germany
    Recruiting
    • Oliver Tomé, Dr. · Contact
  • Studienzentrum Onkologie Ravensburg
    Ravensburg, Baden-Wüttemberg 88212, Germany
    Recruiting
    • Thomas Decker, Prof. Dr.med · Contact
    • Irina Gossen · Contact
  • Klinikum St. Marien Amberg
    Amberg, Bavaria 9224, Germany
    Recruiting
    • Tanja Hauzenberger, Dr. med · Contact
    • Jacqueline Roy · Contact
  • HOP Gemeinschaftspraxis Dres. Heinrich/Bangerter, Augsburg
    Augsburg, Bavaria 86150, Germany
    Recruiting
    • Bernhard Heinrich, Dr. med. · Contact
    • Karin Hillgardt · Contact
  • Universitätsklinikum Augsburg, Brustzentrum
    Augsburg, Bavaria 86156, Germany
    Recruiting
    • Nina Ditsch, Prof. Dr. · Contact
    • Sonja Dannecker · Contact
  • Medias Klinikum
    Burghausen, Bavaria 84489, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Klinikum Fürstenfeldbruck, Westdeutsches Brust- Centrum
    Fürstenfeldbruck, Bavaria 82256, Germany
    Recruiting
    • Konstanze Türpe · Contact
    • Mandy Merwerth · Contact
  • Klinikum der Universität München
    München, Bavaria 80336, Germany
    Recruiting
    • Nadia Harbeck, Prof. Dr. · Contact
    • Beate Rank · Contact
  • Med. Zentrum f. Hämatologie und Onkologie München
    München, Bavaria 80639, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Caritas-Krankenhaus St. Josef, Klinik für Frauenheilkunde & Geburtshilfe
    Regensburg, Bavaria 93053, Germany
    Recruiting
    • Stephan Seitz, Dr. · Contact
    • Cornelia Lämmel · Contact
  • Gemeinschaftskrankenhaus/ Brustzentrum Havelhöhe
    Berlin, Brandenburg 14089, Germany
    Recruiting
    • Jessica Groß, Dr · Contact
    • Antje Merkle · Contact
  • Klinikum Luckenwalde
    Luckenwalde, Brandenburg 14943, Germany
    Recruiting
    • Benedikt Lotz, Dr · Contact
    • Orfea-Graziella Zehm · Contact
  • Universitätsklinikum Erlangen
    Erlangen, Erlangen 91054, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • AGAPLESION Diakonie Hamburg
    Hamburg, Free and Hanseatic City of Hamburg 20259, Germany
    Recruiting
    • Mustafa Celalettin Ugur, Dr. · Contact
    • Mirjam Ahrens · Contact
  • Gynäkologische Praxisklinik Hamburg-Harburg
    Hamburg, Free and Hanseatic City of Hamburg 21073, Germany
    Recruiting
    • Christoph Großmann, Dr. med. · Contact
    • Belma Salihadgic · Contact
  • Asklepios Klinik Barmbek
    Hamburg, Free and Hanseatic City of Hamburg 22307, Germany
    Recruiting
    • Katharina Maria Seiffert, Dr.med. · Contact
    • Sabine Drießelmann · Contact
  • Hämatologie/Onkologie Praxis
    Bremen, Free Hanseatic City of Bremen 28209, Germany
    Recruiting
    • Ralf Meyer, Dr. med. · Contact
    • Heike Munzinger, Dr. nat. · Contact
  • DIAKO Ev. Diakonie-Krankenhaus gemeinnützige GmbH
    Bremen, Free Hanseatic City of Bremen 28239, Germany
    Recruiting
    • Barbara Baloniak, Dr. · Contact
    • Monika Tietze · Contact
  • Klinikum Bremerhaven Reinkenheide
    Bremerhaven, Free Hanseatic City of Bremen 27574, Germany
    Recruiting
    • Amelie Bletscher · Contact
    • Marcelle Lagemann · Contact
  • Gesundheitszentrum Wetterau gGmbH Hochwaldkrankenhaus Bad Nauheim
    Bad Nauheim, Hesse 61231, Germany
    Recruiting
    • Martin Hellriegel, Dr. med. · Contact
    • Anne Groß · Contact
  • Gynäkologische- Geburtshilfliche Klinik
    Bad Soden am Taunus, Hesse 65812, Germany
    Recruiting
    • Johannes Lecht, Dr. · Contact
    • Susanne Hegner, Dpl. · Contact
  • Klinikum Hanau GmbH
    Hanau, Hesse 63450, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Elisabethkrankenhaus Kassel, Brustzentrum
    Kassel, Hesse 34117, Germany
    Recruiting
    • Sabine Schmatloch, Dr. med. · Contact
    • Ivonne Kurzhals · Contact
  • Universität Marburg, Klinik für Frauenheilkunde, Brustzentrum
    Marburg, Hesse 35043, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • St. Josefs-Hospital Wiesbaden GmbH
    Wiesbaden, Hesse 65189, Germany
    Recruiting
    • Antje Lehnert, Dr. med. · Contact
    • Andrea Lunkenheimer · Contact
  • DIAKOVERE Henriettenstift
    Hanover, Lower Saxony 30171, Germany
    Recruiting
    • Kristina Lübbe, Dr. · Contact
    • Laura Alina Löffler · Contact
  • Ärztehaus am Bahnhofsplatz
    Hildesheim, Lower Saxony 31134, Germany
    Recruiting
    • Christopher Uleer, Dr. · Contact
    • Andrea Meyer-Kühn · Contact
  • Studienzentrum Untere Ems
    Leer, Lower Saxony 26789, Germany
    Recruiting
    • Lothar Müller, Dr. med · Contact
    • Christine Strohschnieder · Contact
  • Onkologische Praxis Oldenburg, Gemeinschaftspraxis für Innere Medizin, Hämatologie und Onkologie
    Oldenburg, Lower Saxony 26121, Germany
    Recruiting
    • Daniel Reschke, Dr. · Contact
    • Antje Reschke · Contact
  • Klinikum Südstadt
    Rostock, Mecklenburg-Vorpommern 18059, Germany
    Recruiting
    • Kristin Strauß, Dr. · Contact
    • Michaela Stecher · Contact
  • Marienhospital Aachen
    Aachen, North Rhine-Westphalia 52066, Germany
    Recruiting
    • Esther Geller, Dr. med. · Contact
    • Birgit Dreyer · Contact
  • Gynäkologisches Zentrum
    Bonn, North Rhine-Westphalia 53111, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Bonn Frauenheilkunde
    Bonn, North Rhine-Westphalia 53127, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Bonn, Senologie
    Bonn, North Rhine-Westphalia 53127, Germany
    Recruiting
    • Anne Bachmann · Contact
    • Judith Sailler · Contact
  • Kliniken der Stadt Köln
    Cologne, North Rhine-Westphalia 51067, Germany
    Recruiting
    • Katharina Weinhold, Dr. med. · Contact
    • Claudia Weise · Contact
  • St. Vincenz-Krankenhaus Datteln
    Datteln, North Rhine-Westphalia 45711, Germany
    Recruiting
    • Saskia Hornberg, Dr. · Contact
    • Silvia Schneider · Contact
  • Klinikum Dortmund gGmbH, Beurhausstr.40
    Dortmund, North Rhine-Westphalia 44137, Germany
    Recruiting
    • Claudia Biehl · Contact
    • Jacqueline Aschhoff · Contact
  • Evangelisches Krankenhaus BETHESDA zu Duisburg GmbH, Brustzentrum
    Duisburg, North Rhine-Westphalia 47053, Germany
    Recruiting
    • Katja Engellandt, Dr. med. · Contact
    • Antje auf dem Keller · Contact
  • Luisenkrankenhaus GmbH Co KG
    Düsseldorf, North Rhine-Westphalia 40235, Germany
    Recruiting
    • Athina Kostara, Dr. med. · Contact
    • Anne Huelsewiesche · Contact
  • Marien Hospital Düsseldorf
    Düsseldorf, North Rhine-Westphalia 40479, Germany
    Recruiting
    • Jens-Peter Kruse · Contact
    • David Tschirch · Contact
  • Evang. Kliniken Essen Mitte, Interdisziplinäres Brustkrebszentrum
    Essen, North Rhine-Westphalia 45136, Germany
    Recruiting
    • Sherko Kümmel, Prof.Dr · Contact
    • Dorothea Schindowski · Contact
  • St. Antonius Hospital Kleve (Katholisches Kral Leistner Zentrum)
    Goch, North Rhine-Westphalia 47574, Germany
    Recruiting
    • Volker Runde, Prof. Dr. · Contact
    • Elke Beeker-Cornelissen · Contact
  • AGAPLESION Allgemeines Krankenhaus Hagen
    Hagen, North Rhine-Westphalia 58095, Germany
    Recruiting
    • Nurhayat Yurtcu, Dr. · Contact
    • Tamara Sitnikow · Contact
  • St. Barbara Klinik
    Hamm, North Rhine-Westphalia 59073, Germany
    Recruiting
    • Claudia Strunk, Dr. · Contact
    • Gabriele Kerkmann · Contact
  • Gemeinschaftskrankenhaus Herdecke gemeinnützige GmbH
    Herdecke, North Rhine-Westphalia 58313, Germany
    Recruiting
    • Hanne- Kathrin Bracht · Contact
    • Jasmin Schiprowski · Contact
  • Klinikum Leverkusen, Am Gesundheitspark
    Leverkusen, North Rhine-Westphalia 51375, Germany
    Recruiting
    • Andrea Heider, Dr. · Contact
    • Katja Pöggel-Krämer · Contact
  • Katholisches Klinikum Lünen/Werne
    Lünen, North Rhine-Westphalia 44534, Germany
    Recruiting
    • Donat Romann, Dr. · Contact
    • Ute Heine · Contact
  • Brustzentrum Niederrhein, Johanniter Bethesda Krankenhaus
    Mönchengladbach, North Rhine-Westphalia 41061, Germany
    Recruiting
    • Oleg Gluz, PD Dr. · Contact
    • Carolin Sydlik · Contact
  • St. Franziskus-Hospital
    Münster, North Rhine-Westphalia 48145, Germany
    Recruiting
    • Christian Eichler, PD Dr. · Contact
    • Sarah Damerau · Contact
  • Universitaetsklinikum Muenster
    Münster, North Rhine-Westphalia 48149, Germany
    Recruiting
    • Joke Tio, Dr. · Contact
    • Stefanie Nienkemper · Contact
  • Frauenklinik St. Louise - St. Vincenz-Krankenhaus GmbH
    Paderborn, North Rhine-Westphalia 33098, Germany
    Recruiting
    • Michael-Patrick Lux, Prof. Dr. · Contact
    • Sara Heimann · Contact
  • Mathias-Spital-Rheine
    Rheine, North Rhine-Westphalia 48431, Germany
    Recruiting
    • Sebastian Bröckling, Dr. med. · Contact
    • Denise Ernst · Contact
  • Praxisnetzwerk Hämatologie/int. Onkologie
    Troisdorf, North Rhine-Westphalia 53840, Germany
    Recruiting
    • Helmut Forstbauer, Dr. med. · Contact
    • Stefanie Vorpahl · Contact
  • Christliches Klinikum Unna gGmbH
    Unna, North Rhine-Westphalia 59423, Germany
    Recruiting
    • Cristin Kühn, Dr. med. · Contact
    • Vanessa Schuster · Contact
  • Evangelisches Krankenhaus Wesel GmbH
    Wesel, North Rhine-Westphalia 46485, Germany
    Recruiting
    • Daniela Rezek, Dr. med. · Contact
    • Shqipe Lorito · Contact
  • Helios Klinikum Wuppertal
    Wuppertal, North Rhine-Westphalia 42283, Germany
    Recruiting
    • Vesna Bjelic-Radisic, Prof. Dr. · Contact
    • Manuela Smiljanic · Contact
  • Klinikum Worms
    Worms, Rhineland-Palatinate 67550, Germany
    Recruiting
    • Antje Nixdorf, Dr. med. · Contact
    • Tanja Knoll · Contact
  • Krankenhaus St. Elisabeth und St. Barbara Halle/Saale
    Halle, Saxony-Anhalt 06110, Germany
    Recruiting
    • Tilmann Lantzsch, Dr. med. · Contact
    • Mandy Babbe · Contact
  • Altmark- Klinikum
    Hansestadt Salzwedel, Saxony-Anhalt 29410, Germany
    Recruiting
    • Susanne Kraudelt, Dr. · Contact
    • Steffi Mack-Eichner · Contact
  • Medionko - Praxisklinik Krebsheilkunde Frauen
    Berlin, State of Berlin 10367, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • St. Gertrauden Krankenhaus Brustzentrum City Berlin
    Berlin, State of Berlin 10713, Germany
    Recruiting
    • Lidia Perlova-Griff · Contact
    • Michaela Platzer · Contact
  • DRK Kliniken Berlin Köpenick
    Berlin, State of Berlin 12559, Germany
    Recruiting
    • Anke Kleine-Tebbe, Dr. med. · Contact
    • Manuela Rösler · Contact
  • Marienhospital, Klinik für Gynäkologie und Geburtshilfe
    Bottrop, Germany
    Recruiting
    • Hans-Christian Kolberg, PD Dr. · Contact
    • Jessica Zeller · Contact
  • Helios Klinikum Krefeld, Zentrum für Ambulante Gynäkologische Onkologie - Studienabteilung
    Krefeld, Germany
    Recruiting
    • Maria Marina Wirtz, Dr. med. · Contact
    • Laura Mengel · Contact
  • MKS St. Paulus Schwerte (ehemals Marienkrankenhaus)
    Schwerte, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Klinikum Traunstein, Frauenklinik Südostbayern
    Traunstein, Germany
    Recruiting
    • Christian Schindlbeck, Prof. Dr. · Contact
    • Christina Greil · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Mar 2035, 147 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 147 months is above that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2023
First posted
Mar 31, 2023
StartActual
Dec 7, 2022
Primary completionEst.
Mar 2035
CompletionEst.
Jun 2035
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05792150
Lead sponsor
Women's Cancer Study Group GmbH
Collaborators
Agendia
Responsible party
Sponsor
First posted
Mar 31, 2023
Start date
Dec 7, 2022
Primary completion
Mar 2035 (estimated)
Completion
Jun 2035 (estimated)
Last update
Aug 5, 2026

Study contacts

Julian Moellers
Contact
julian.moellers@wsg-online.com
00492161566 23-0
Anja Braschoss, MD
Contact
anja.braschoss@wsg-online.com
04917682119153
Oleg Gluz, PD Dr.
principal investigator · Westdeutsche Studiengruppe GmbH
Rachel Wuerstlein, Prof. Dr.
principal investigator · Westdeutsche Studiengruppe GmbH
Monika Graeser, PD Dr.
study director · Westdeutsche Studiengruppe GmbH
Nadia Harbeck, Prof. Dr.
principal investigator · LMU Clinics, Breast Centre and CCC
Sherko Kuemmel, Prof. Dr.
principal investigator · KEM, Clinics Essen-Mitte
Ulrike Nitz, Prof. Dr.
study director · Westdeutsche Studiengruppe GmbH
Andreas Hartkopf, Prof. Dr.
principal investigator · Univewrsity Hospital Tuebingen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion